Sumifilam Drug Asset Due Diligence Report 2026

This Sumifilam Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Sumifilam can convert its Small molecule drug profile and FLNA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Sumifilam (query alias: Sumifilam)
Modality / target	Small molecule drug; FLNA; FLNA modulators, Microfilament proteins inhibitors
Highest global status	Phase 1
Originator	Filana Therapeutics, Inc.
Active developers	Filana Therapeutics, Inc.

The MCP disease footprint includes Epilepsy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05575076	Phase 3	Terminated	1081	Number of Participants With Adverse Events
NCT05352763	Phase 2	Terminated	90	Adverse Event Monitoring
NCT06390410	Phase 1	Completed	27	Area Under the Curve; moderate vs. normal and mild vs. normal

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease

Phase 3; n=1929; evaluation: Negative. Reported fields: cognitive decline(Week 64): P-Value = 0.019; cognitive decline(Week 64): P-Value = 0.019; cognitive decline(Week 64): P-Value = 0.019

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease

Phase 3; n=1125; evaluation: not stated. Reported fields: Change From Baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12)(Least Squares Mean) = 5.26 score on a scale (Standard Error, 0.506); Change From Baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12)(Least Squares Mean) = 5.71 score on a scale (Standard Error, 0.529); Change From Baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12)(Least Squares Mean) = 5.65 score on a scale (Standard Error, 0.509)

An Open-Label Extension of the PTI-125-04 Study Evaluating the Safety and Long-Term Treatment of Simufilam in Mild-to-Moderate Alzheimer's Disease Patients

Phase 2; n=90; evaluation: not stated. Reported fields: Adverse Event Monitoring = 90 Participants ; -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Sumifilam addresses Epilepsy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-02-27	Cassava Sciences Licenses Simufilam Method of Treatment Patent to Yale University	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Solid polymorphs of a FLNA-binding compound and its hydrochloride salts”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION